TC BIOPHARM HOLDINGS PLC Stock Price, News & Analysis
Company Description
TC BioPharm (Holdings) PLC Warrants (NASDAQ: TCBPW) are equity-linked securities associated with TC BioPharm (Holdings) PLC, a clinical-stage biopharmaceutical company. TC BioPharm focuses on the discovery, development and commercialization of gamma-delta T cell therapies for the treatment of cancer, with human efficacy data reported in acute myeloid leukemia (AML). The warrants relate to the company’s capital structure and provide exposure to TC BioPharm’s oncology-focused cell therapy platform.
TC BioPharm is described as a clinical-stage biotechnology and biopharmaceutical company developing platform allogeneic gamma-delta T cell therapies for cancer. Gamma-delta T cells are naturally occurring immune cells that embody properties of both the innate and adaptive immune systems and can intrinsically differentiate between healthy and diseased tissue. According to the company’s statements, it uses an allogeneic approach in both unmodified and CAR modified gamma-delta T cells to effectively identify, target and eradicate both liquid and solid tumors in cancer.
The company states that it is the leader in developing gamma-delta T cell therapies and the first company to conduct phase II/pivotal clinical studies in oncology using this approach. TC BioPharm reports human efficacy data in AML and is conducting investigator-initiated clinical trials for its unmodified gamma-delta T cell product line. A key program is a Phase 2b/3 pivotal trial for OmnImmune® in the treatment of acute myeloid leukemia, using the company’s proprietary allogenic CryoTC technology to provide frozen product to clinics worldwide.
In addition to its AML program, TC BioPharm states that it maintains a robust pipeline for future indications in solid tumors. The company highlights a significant intellectual property and patent portfolio in the use of chimeric antigen receptors (CARs) with gamma-delta T cells. It also notes that it owns its manufacturing facility, which it cites as a way to maintain cost and product quality controls for its cell therapy products.
TC BioPharm’s research and clinical work includes a Phase I trial of allogeneic gamma-delta T lymphocytes from haploidentical donors in patients with refractory or relapsed AML, which was published in a peer-reviewed journal. The company describes this study as demonstrating the safety and feasibility of this type of cell therapy and as the basis for its next steps in the allogeneic cell therapy sector. The publication is presented by the company as a hallmark moment, marking its first scientific paper generated from its clinical program.
The company has also announced a strategic collaboration with The University of Texas MD Anderson Cancer Center. Under this three-year agreement, TC BioPharm and MD Anderson plan to work together on preclinical and clinical studies to evaluate the potential for gamma-delta T cell therapies and to better understand the behavior of these cells in patients. The collaboration is intended to expand the knowledge base of how gamma-delta T cells work in oncology settings and to inform the design of future studies, including potential targeted cancer studies in other blood cancers and solid tumors.
TC BioPharm describes itself as operating in the allogeneic gamma-delta T cell space with both unmodified and CAR modified approaches, and emphasizes its clinical-stage status through ongoing trials and collaborations. For investors and observers of TCBPW, these warrants are linked to a company that focuses on immuno-oncology research and development, particularly around gamma-delta T cell platforms for cancer treatment.
From a corporate and regulatory perspective, TC BioPharm (Holdings) PLC is identified as a foreign private issuer that files reports under Form 20-F. A Form 6-K filing describes the results of the company’s 2025 Annual General Meeting, where shareholders voted on matters such as receipt of the annual report and audited financial statements, approval of the directors’ remuneration report, re-appointment of the U.K. statutory auditor, authorization of the audit committee to determine auditor remuneration, share subdivision and reclassification, share allotment authorities, disapplication of pre-emption rights, amendments to the Articles of Association to create B Deferred Shares, and authorization for off-market purchases of B Deferred Shares.
Regarding trading status, a Form 25 (25-NSE) filing indicates that the American Depositary Shares, Warrant class of securities of TC BioPharm (Holdings) PLC was removed from listing and/or registration on The Nasdaq Stock Market LLC under Section 12(b) of the Securities Exchange Act of 1934. The notification states that Nasdaq Stock Market LLC has complied with its rules to strike the class of securities from listing and/or withdraw registration on the exchange. This filing confirms that the warrant class associated with TCBPW has been delisted from Nasdaq, although the form does not itself describe any change to the underlying business operations.
According to the company’s own descriptions in its news releases, TC BioPharm continues to focus on its gamma-delta T cell therapy platform, clinical trials in AML, and planned or ongoing collaborations. The warrants represented by the ticker TCBPW are historically tied to this biopharmaceutical issuer and its oncology-focused research and development efforts.